Background Background There is an excess of
There is an excess of death from natural causes among people death from natural causes among people with schizophrenia. with schizophrenia.
Aims Aims Schizophrenia and its treatment
Schizophrenia and its treatment with neuroleptics were studied for their with neuroleptics were studied for their prediction of mortality in a representative prediction of mortality in a representative population sample of 7217 Finns aged population sample of 7217 Finns aged 5 530 30
years. years.
Method
Method A comprehensive health A comprehensive health examination was carried out at baseline. examination was carried out at baseline. Schizophrenia was determined using the Schizophrenia was determined using the Present State Examination and previous Present State Examination and previous medical records. medical records.
Results

Results During a17-year follow-up, 39
During a17-year follow-up, 39 of the 99 people with schizophrenia died. of the 99 people with schizophrenia died. Adjusted for age and gender, the relative Adjusted for age and gender, the relative mortality risk between those with schizomortality risk between those with schizophrenia and others was 2.84 (95% CI phrenia and others was 2.84 (95% CI 2.06^3.90), andwas 2.25 (95% CI1.61^3.15) 2.06^3.90), andwas 2.25 (95% CI1.61^3.15) after further adjusting for somatic after further adjusting for somatic diseases, diseases,blood bloodpressure, pressure,cholesterol,body cholesterol,body mass index, smoking, exercise, alcohol mass index, smoking, exercise, alcohol intakeandeducation.Thenumberofneurointakeandeducation.Thenumberofneuroleptics used atthe time of the baseline leptics used atthe time of the baseline survey showed a graded relation to survey showed a graded relation to mortality. Adjusted for age, gender, mortality. Adjusted for age, gender, somatic diseases and other potential risk somatic diseases and other potential risk factors for premature death, the relative factors for premature death, the relative risk was 2.50 (95% CI1.46^4.30) per risk was 2.50 (95% CI1.46^4.30) per increment of one neuroleptic. increment of one neuroleptic.
Conclusions Conclusions Thereis an urgent needto
Thereis an urgent need to ascertain whether the high mortalityin ascertainwhether the high mortalityin schizophreniais attributabletothe disorder schizophreniais attributabletothe disorder itself or the antipsychotic medication. itself or the antipsychotic medication.
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Excess mortality among people with schizoExcess mortality among people with schizophrenia is partly a result of suicide (Brown, phrenia is partly a result of suicide (Brown, 1997; Harris & Barraclough, 1998; Heila 1997; Harris & Barraclough, 1998; Heilä & Lonnqvist, 2003) but is also attributable & Lö nnqvist, 2003) but is also attributable to natural deaths (Brown, 1997; Mortento natural deaths (Brown, 1997; Mortensen, 2003) , obviously explained by dietary sen, 2003), obviously explained by dietary and lifestyle factors (Brown, 1997) and and lifestyle factors (Brown, 1997) and possibly by use of neuroleptics (Montout possibly by use of neuroleptics (Montout et al et al, 2002; Ray & Meador, 2002) . Most , 2002; Ray & Meador, 2002) . Most studies have included small and nonstudies have included small and nonrepresentative series of patients, short representative series of patients, short follow-up and no control for confounding follow-up and no control for confounding factors. In a representative population factors. In a representative population sample over a long follow-up period, we sample over a long follow-up period, we found schizophrenia to be associated with found schizophrenia to be associated with excess mortality. In males this was owing excess mortality. In males this was owing to cardiovascular diseases (especially to cardiovascular diseases (especially coronary disease), suicides and respiratory coronary disease), suicides and respiratory diseases and in females to cerebrovascular diseases and in females to cerebrovascular and respiratory diseases (Joukamaa and respiratory diseases (Joukamaa et al et al, , 2001 ). In the present study schizophrenia 2001). In the present study schizophrenia and its treatment with neuroleptic mediand its treatment with neuroleptic medication were studied for their prediction of cation were studied for their prediction of mortality. We aimed to assess the effects mortality. We aimed to assess the effects of socio-demographic and lifestyle factors of socio-demographic and lifestyle factors and somatic health on the mortality and somatic health on the mortality differentials. differentials.
METHOD METHOD
The current study was based on the MiniThe current study was based on the MiniFinland Health Survey (Aromaa Finland Health Survey (Aromaa et al et al, , 1989) . This comprehensive survey, carried 1989). This comprehensive survey, carried out between 1978 and 1980, was designed out between 1978 and 1980, was designed to assess the health of adult Finns. The to assess the health of adult Finns. The study population was a two-stage cluster study population was a two-stage cluster sample drawn from the population register sample drawn from the population register and stratified to represent Finns aged 30 and stratified to represent Finns aged 30 years or over. The first stage comprised years or over. The first stage comprised the selection of 40 representative areas. In the selection of 40 representative areas. In the second stage a systematic sample of the second stage a systematic sample of inhabitants was drawn from each area. inhabitants was drawn from each area. The sample size was 8000 persons, of The sample size was 8000 persons, of whom 7217 (90%) participated in the whom 7217 (90%) participated in the health examination (Aromaa health examination (Aromaa et al et al, 1989) . , 1989). The participants were first interviewed The participants were first interviewed at home by local public health nurses and at home by local public health nurses and examined 1-6 weeks later by the Mobile examined 1-6 weeks later by the Mobile Clinic of the Social Insurance Institution Clinic of the Social Insurance Institution (SII) in two phases: a screening phase and (SII) in two phases: a screening phase and a diagnostic (clinical) phase. The measurea diagnostic (clinical) phase. The measurements of the screening phase, the methods ments of the screening phase, the methods used for studying chronic diseases and the used for studying chronic diseases and the basic results of the Mini-Finland Health basic results of the Mini-Finland Health Survey have been previously described in Survey have been previously described in detail (Aromaa detail (Aromaa et al et al, 1989; Makela , 1989; Mä kelä et al et al, , 1993) . People with a disease history, symp-1993). People with a disease history, symptoms or findings suggestive of chronic distoms or findings suggestive of chronic diseases were asked to participate in the eases were asked to participate in the diagnostic (clinical) phase, which was on diagnostic (clinical) phase, which was on average 3.5 months after the screening average 3.5 months after the screening examination. Cardiovascular and respiraexamination. Cardiovascular and respiratory diseases, diabetes and other somatic tory diseases, diabetes and other somatic conditions were diagnosed on the basis of conditions were diagnosed on the basis of medical history, symptoms, physical medical history, symptoms, physical examination and findings of the screening examination and findings of the screening phase (Aromaa phase (Aromaa et al et al, 1989; Makela , 1989; Mä kelä et al et al, , 1993) . 1993).
Screening procedure Screening procedure
The methods used and the basic findings The methods used and the basic findings concerning mental disorders in the Miniconcerning mental disorders in the MiniFinland Health Survey have been described Finland Health Survey have been described in detail elsewhere (Lehtinen in detail elsewhere (Lehtinen et al et al, , 1990 (Lehtinen et al et al, , 1990a . The screening for mental dis-). The screening for mental disorders comprised several parts. We tried orders comprised several parts. We tried to make the screen as sensitive as possible to make the screen as sensitive as possible in order to minimise the number of falsein order to minimise the number of falsenegative cases, as no screen-negative people negative cases, as no screen-negative people were invited to participate in the clinical were invited to participate in the clinical phase of the study. The most important phase of the study. The most important part of the screen was the 36-item version part of the screen was the 36-item version of the General Health Questionnaire (Goldof the General Health Questionnaire (Goldberg, 1972) . People were also invited to berg, 1972). People were also invited to participate in the clinical phase if the participate in the clinical phase if the records in the SII indicated that they were records in the SII indicated that they were receiving a disability pension because of a receiving a disability pension because of a mental disorder or were entitled to remental disorder or were entitled to reimbursement for medication for such disimbursement for medication for such disorders (according to the National Health orders (according to the National Health Insurance Scheme in Finland, all psychoses Insurance Scheme in Finland, all psychoses entitle the individual to free medication entitle the individual to free medication for their treatment). People were also sefor their treatment). People were also selected if they reported having used health lected if they reported having used health services (including those provided by a genservices (including those provided by a general practitioner) for a mental disorder or eral practitioner) for a mental disorder or there was a self-perceived mental disorder. there was a self-perceived mental disorder. A total of 35% of those who participated A total of 35% of those who participated in the screening phase were identified by in the screening phase were identified by various screening instruments; 95% of various screening instruments; 95% of these agreed to participate in the clinical these agreed to participate in the clinical phase of the health examination. phase of the health examination.
Case-finding procedure Case-finding procedure et al, 1978) . Diag-, 1978) . Diagnostic information was also obtained from: nostic information was also obtained from: case notes of participants in in-patient psycase notes of participants in in-patient psychiatric care; SII records on disability penchiatric care; SII records on disability pensions granted because of a mental disorder sions granted because of a mental disorder and on reimbursement for medication to and on reimbursement for medication to treat psychoses; examination by the physitreat psychoses; examination by the physician in the clinical phase of the survey; cian in the clinical phase of the survey; and assessment by the psychiatric nurse and assessment by the psychiatric nurse conducting the PSE interview. A panel of conducting the PSE interview. A panel of two psychiatrists reviewed the case notes two psychiatrists reviewed the case notes of in-patients and the psychiatric records of in-patients and the psychiatric records entitling individuals to SII benefits (disabilentitling individuals to SII benefits (disability pensions and reimbursement for mediity pensions and reimbursement for medicines) to validate the diagnoses. For the cines) to validate the diagnoses. For the final diagnostic assessments, a special comfinal diagnostic assessments, a special computer program was designed that combined puter program was designed that combined information from various sources, taking information from various sources, taking into account the degree of certainty and into account the degree of certainty and eliminating mutually incompatible eliminating mutually incompatible assessment combinations. There were 99 assessment combinations. There were 99 people with a diagnosis of schizophrenia, people with a diagnosis of schizophrenia, giving an age-adjusted prevalence of 1.3% giving an age-adjusted prevalence of 1.3% with no gender difference (Lehtinen with no gender difference (Lehtinen et al et al, , 1990 (Lehtinen et al et al, , 1990a ; this was in accordance with an ear-); this was in accordance with an earlier population study in Finland (Vaisanen, lier population study in Finland (Vaisanen, 1975 (Vaisanen, ). 1975 .
The mortality of those examined has The mortality of those examined has been systematically monitored since the been systematically monitored since the baseline assessment. This information was baseline assessment. This information was obtained from the Central Statistical Office obtained from the Central Statistical Office of Finland. The principal causes of death of Finland. The principal causes of death were coded according to ICD-8 (World were coded according to ICD-8 (World Health Organization, 1974) (8) by respiratory diseases; 341 (7) by cancers; respiratory diseases; 341 (7) by cancers; 72 (2) by injuries; and 20 (2) by suicides. 72 (2) by injuries; and 20 (2) by suicides.
The definitions and measurement of The definitions and measurement of lifestyle and related factors (level of edulifestyle and related factors (level of education, exercise, smoking, alcohol intake, cation, exercise, smoking, alcohol intake, body mass index, systolic and diastolic body mass index, systolic and diastolic blood pressure, serum total and highblood pressure, serum total and highdensity lipoprotein (HDL) cholesterol) have density lipoprotein (HDL) cholesterol) have been described in more detail elsewhere been described in more detail elsewhere (Aromaa (Aromaa et al et al, 1989; Makela , 1989; Mä kelä et al et al, 1993) . , 1993). Participants were asked about drugs preParticipants were asked about drugs prescribed by their physician. The use of scribed by their physician. The use of neuroleptic drugs among people with neuroleptic drugs among people with schizophrenia was also recorded in the schizophrenia was also recorded in the screening phase and was categorised screening phase and was categorised according to the number prescribed. At according to the number prescribed. At the time of the baseline assessment the the time of the baseline assessment the following conventional neuroleptics were following conventional neuroleptics were the only neuroleptic drugs in use in Finland: the only neuroleptic drugs in use in Finland: phenothiazines with an aliphatic side-chain phenothiazines with an aliphatic side-chain (promazine, chlorpromazine, levome-(promazine, chlorpromazine, levomepromazine); phenothiazines with a methylpromazine); phenothiazines with a methylpiperazine side-chain (thioproperazine, piperazine side-chain (thioproperazine, trifluoperazine); phenothiazines with a trifluoperazine); phenothiazines with a piperazine-ethanol side-chain (perphenpiperazine-ethanol side-chain (perphenazine, fluphenazine, thiopropazate); pheazine, fluphenazine, thiopropazate); phenothiazines with a piperidine side-chain nothiazines with a piperidine side-chain (thioridazine, pericyazine, pipotiazine); (thioridazine, pericyazine, pipotiazine); thioxanthenes (chlorprothixene, clopenthioxanthenes (chlorprothixene, clopenthixol, flupenthixol, thiothixene); butyrothixol, flupenthixol, thiothixene); butyrophenones (haloperidol, melperone, phenones (haloperidol, melperone, moperone); piperazines (pimozide); benzamoperone); piperazines (pimozide); benzamides (sulpiride); and indoles (oxyperine). mides (sulpiride); and indoles (oxyperine).
A number of factors may be associated A number of factors may be associated both with schizophrenia and mortality and both with schizophrenia and mortality and could therefore confound the analysis. could therefore confound the analysis. Age, gender, level of education, smoking, Age, gender, level of education, smoking, alcohol intake, exercise, body mass index, alcohol intake, exercise, body mass index, systolic and diastolic pressure, serum total systolic and diastolic pressure, serum total and HDL cholesterol, diabetes, cardioand HDL cholesterol, diabetes, cardiovascular and respiratory diseases and other vascular and respiratory diseases and other somatic diseases were therefore considered somatic diseases were therefore considered potential confounders or effect modifiers potential confounders or effect modifiers in the present study (Brown, 1997;  in the present study (Brown, 1997; Mortensen, 2003) . Mortensen, 2003) .
Statistical analysis Statistical analysis
Logistic regression was used to estimate the Logistic regression was used to estimate the associations between the potential conassociations between the potential confounding and effect-modifying factors and founding and effect-modifying factors and the prevalence of schizophrenia. The generthe prevalence of schizophrenia. The general linear model was used to compute multial linear model was used to compute multiple partial correlation ratios between those ple partial correlation ratios between those factors and the number of neuroleptic drugs factors and the number of neuroleptic drugs among participants with schizophrenia. among participants with schizophrenia. Cox's proportional hazards regression Cox's proportional hazards regression model (Cox, 1972) was used to estimate model (Cox, 1972) was used to estimate the strength of the association between the strength of the association between schizophrenia and mortality and between schizophrenia and mortality and between neuroleptic drug use for schizophrenia and neuroleptic drug use for schizophrenia and mortality. The number of neuroleptic drugs mortality. The number of neuroleptic drugs for schizophrenia was included both as a for schizophrenia was included both as a categorical variable and as a continuous categorical variable and as a continuous variable in the model. Potential confoundvariable in the model. Potential confounding and effect-modifying factors were ing and effect-modifying factors were entered into the Cox models. Adjusted relaentered into the Cox models. Adjusted relative risks and their 95% confidence intertive risks and their 95% confidence intervals (CIs) were estimated based on this vals (CIs) were estimated based on this model. The SAS software package version model. The SAS software package version 6.12 (SAS Institute, 1997) was used. 6.12 (SAS Institute, 1997) was used.
RESULTS RESULTS
At baseline a number of lifestyle-related At baseline a number of lifestyle-related factors and chronic diseases were assofactors and chronic diseases were associated with the prevalence of schizophrenia. ciated with the prevalence of schizophrenia. Since some of the associations seemed to Since some of the associations seemed to differ between men and women, all these differ between men and women, all these results were stratified according to gender results were stratified according to gender (Tables 1 and 2 ). Heavy smoking and (Tables 1 and 2 ). Heavy smoking and obesity were significantly associated with obesity were significantly associated with schizophrenia in both men and women, schizophrenia in both men and women, whereas being underweight proved to be a whereas being underweight proved to be a significant determinant only in men, and significant determinant only in men, and diabetes and other somatic diseases in diabetes and other somatic diseases in women. Inverse associations with schizowomen. Inverse associations with schizophrenia emerged for alcohol intake and phrenia emerged for alcohol intake and serum HDL cholesterol in both men and serum HDL cholesterol in both men and women; in women there was an inverse women; in women there was an inverse association for exercise and in men for association for exercise and in men for systolic pressure. systolic pressure.
The age-and gender-adjusted relative The age-and gender-adjusted relative risk of total mortality between people with risk of total mortality between people with schizophrenia and others was 2.84 (95% CI schizophrenia and others was 2.84 (95% CI 2.06-3.90). The risk of mortality was in-2.06-3.90). The risk of mortality was increased among people with schizophrenia creased among people with schizophrenia even after controlling for potential risk even after controlling for potential risk factors for premature death (low level of factors for premature death (low level of education, smoking, alcohol intake, exereducation, smoking, alcohol intake, exercise, body mass index, systolic and diastolic cise, body mass index, systolic and diastolic pressure, and total and HDL cholesterol) pressure, and total and HDL cholesterol) and coexistent somatic diseases (Table 3) . and coexistent somatic diseases (Table 3) . As there was no difference between men As there was no difference between men and women in the association between and women in the association between schizophrenia and mortality, they were schizophrenia and mortality, they were combined in these analyses. combined in these analyses.
There were only four unnatural deaths There were only four unnatural deaths among those with schizophrenia. Adjusted among those with schizophrenia. Adjusted for age and gender, the relative risk of for age and gender, the relative risk of natural death between people with schizonatural death between people with schizophrenia and others was 2.80 (95% CI phrenia and others was 2.80 (95% CI 2.00-3.93). 2.00-3.93).
Of the 99 people with schizophrenia, Of the 99 people with schizophrenia, 20 were taking no neuroleptic drug at base-20 were taking no neuroleptic drug at baseline, 31 one drug, 34 two drugs and 14 line, 31 one drug, 34 two drugs and 14 three or more drugs. The most commonly three or more drugs. The most commonly used neuroleptic was thioridazine (34%), used neuroleptic was thioridazine (34%), followed by perphenazine (20%), chlorfollowed by perphenazine (20%), chlorpromazine (19%), levomepromazine (14%), promazine (19%), levomepromazine (14%), chlorprothixene (13%) and haloperidol chlorprothixene (13%) and haloperidol (12%); use of other neuroleptics was less (12%); use of other neuroleptics was less than 10%. Among participants with schizothan 10%. Among participants with schizophrenia, there was a strong inverse rephrenia, there was a strong inverse relationship between serum HDL cholesterol lationship between serum HDL cholesterol and the number of neuroleptic drugs preand the number of neuroleptic drugs prescribed (correlation coefficient scribed (correlation coefficient¼7 70.41, 0.41, P P5 50.001) that 0.001) that remained statistically remained statistically significant after adjust significant after adjustment for age, gender, ment for age, gender, all lifestyle-related factors and coexistent all lifestyle-related factors and coexistent somatic diseases (partial corresomatic diseases (partial correlation lation¼7 70.31, 0.31, P P¼0.007). Smoking was 0.007). Smoking was also associated with the number of neuroalso associated with the number of neuroleptics prescribed (correlation coefficient leptics prescribed (correlation coefficient¼ 0.35, 0.35, P P¼0.007), but the association did 0.007), but the association did not reach statistical significance in the not reach statistical significance in the multifactorial analysis (partial correlation multifactorial analysis (partial correlation ¼0.27, 0.27, P P¼0.14). 0.14). The number of neuroleptic drugs The number of neuroleptic drugs prescribed at the time of the baseline survey prescribed at the time of the baseline survey was related to the subsequent mortality. Of was related to the subsequent mortality. Of people with schizophrenia taking one, two people with schizophrenia taking one, two and three or more neuroleptic drugs, 11 and three or more neuroleptic drugs, 11 (35%), 15 (44%) and 8 (57%) respectively (35%), 15 (44%) and 8 (57%) respectively died during follow-up, whereas the died during follow-up, whereas the corresponding rate was 5 (20%) among corresponding rate was 5 (20%) among those without neuroleptic medication. those without neuroleptic medication. Table 4 shows the relative risk of dying Table 4 shows the relative risk of dying among those with schizophrenia per increamong those with schizophrenia per increment of one neuroleptic drug adjusted for ment of one neuroleptic drug adjusted for age, gender, lifestyle-related factors and age, gender, lifestyle-related factors and chronic somatic diseases. Irrespective of chronic somatic diseases. Irrespective of the factors modelled, the relationship the factors modelled, the relationship between number of neuroleptic drugs and between number of neuroleptic drugs and mortality remained strong and statistically mortality remained strong and statistically significant. significant. To assess the combined effect of schizoTo assess the combined effect of schizophrenia and the number of neuroleptic phrenia and the number of neuroleptic drugs in the whole of the study population, drugs in the whole of the study population, the 68 people taking neuroleptics for other the 68 people taking neuroleptics for other psychoses were excluded. Adjusted for age psychoses were excluded. Adjusted for age and gender, people with schizophrenia takand gender, people with schizophrenia taking no neuroleptic, one, two and three or ing no neuroleptic, one, two and three or more neuroleptic drugs had relative risks more neuroleptic drugs had relative risks (95% CI) of 1.29 (0.53-3.11), 2.97 (1.64-(95% CI) of 1.29 (0.53-3.11), 2.97 (1. 64-5.38), 3.21 (1.93-5.35) and 6.83 (3.40-5.38), 3.21 (1.93-5.35) and 6.83 (3.40-13.71 ) respectively compared with those 13.71) respectively compared with those without schizophrenia or any antipsychotic without schizophrenia or any antipsychotic treatment with neuroleptics. The associatreatment with neuroleptics. The association remained stable throughout the obsertion remained stable throughout the observation period. Even after excluding the first vation period. Even after excluding the first 10 years of follow-up, the corresponding 10 years of follow-up, the corresponding estimates were 1. 69 (0.42-6.80 
DISCUSSION DISCUSSION
Main findings Main findings
The present study demonstrated a graded The present study demonstrated a graded relationship between the number of neurorelationship between the number of neuroleptic drugs prescribed and mortality of leptic drugs prescribed and mortality of those with schizophrenia. This relationship those with schizophrenia. This relationship and the excess mortality among people and the excess mortality among people with schizophrenia could not be explained with schizophrenia could not be explained by coexistent somatic diseases or other by coexistent somatic diseases or other known risk factors for premature death. known risk factors for premature death. To our knowledge this was the first study To our knowledge this was the first study to analyse such associations in the general to analyse such associations in the general population using a prospective design. population using a prospective design.
Although the excess mortality of people Although the excess mortality of people with schizophrenia was first demonstrated with schizophrenia was first demonstrated before the Second World War, the causes before the Second World War, the causes have varied over the years, especially before have varied over the years, especially before the neuroleptic era (see Brown, 1997) . It the neuroleptic era (see Brown, 1997) . It has been claimed that the contemporary has been claimed that the contemporary high natural mortality in schizophrenia high natural mortality in schizophrenia results from a variety of lifestyle factors results from a variety of lifestyle factors (Brown, 1997; Mortensen, 2003) . Of these (Brown, 1997; Mortensen, 2003) . Of these factors we were able to consider several factors we were able to consider several (smoking, exercise, body mass index, blood (smoking, exercise, body mass index, blood pressure, serum total and HDL cholesterol), pressure, serum total and HDL cholesterol), but not all (e.g. dietary factors). However, but not all (e.g. dietary factors). However, after adjustment for these factors the excess after adjustment for these factors the excess mortality of people with schizophrenia mortality of people with schizophrenia persisted. Similarly, comorbid somatic persisted. Similarly, comorbid somatic diseases did not account for the mortality. diseases did not account for the mortality. Obviously there are other factors associated Obviously there are other factors associated with mortality in schizophrenia and the with mortality in schizophrenia and the association with neuroleptic drugs was very association with neuroleptic drugs was very clear. This remained after adjustment for clear. This remained after adjustment for many different potentially confounding many different potentially confounding factors. At the time of the baseline survey factors. At the time of the baseline survey only classic neuroleptic drugs were in use only classic neuroleptic drugs were in use in Finland. in Finland.
It is now well known that most or all It is now well known that most or all classic neuroleptics can cause prolongation classic neuroleptics can cause prolongation of the QT interval of the electrocardiogram of the QT interval of the electrocardiogram 12 5 12 5 Table 2  Table 2 Odds ratio for schizophrenia according to blood pressure and cholesterol levels Odds ratio for schizophrenia according to blood pressure and cholesterol levels which is associated with the potentially which is associated with the potentially fatal arrhythmia torsade de pointes fatal arrhythmia torsade de pointes (Witchel (Witchel et al et al, 2003) . Recently, in a large , 2003) . Recently, in a large study Ray study Ray et al et al (2001) showed that (2001) showed that prescription of moderate doses of antipsyprescription of moderate doses of antipsychotics was associated with large relative chotics was associated with large relative and absolute increases in the risk of sudden and absolute increases in the risk of sudden cardiac death. It has been proposed that cardiac death. It has been proposed that antipsychotic drugs might also be assoantipsychotic drugs might also be associated with venous thrombosis, pulmonary ciated with venous thrombosis, pulmonary embolism (Thomassen embolism (Thomassen et al et al, 2001) and , 2001 ) and asthma mortality (Joseph asthma mortality (Joseph et al et al, 1996) . These , 1996) . These associations could explain at least some of associations could explain at least some of the deaths from respiratory diseases in the the deaths from respiratory diseases in the present study. present study.
Neuroleptic polypharmacy Neuroleptic polypharmacy
The risk of dying increased in our study if The risk of dying increased in our study if the participants were taking more than the participants were taking more than one neuroleptic drug. This is in line with one neuroleptic drug. This is in line with previous findings. Waddington previous findings. Waddington et al et al (1998) found that receiving more than one (1998) found that receiving more than one antipsychotic concurrently was associated antipsychotic concurrently was associated with reduced survival in a 10-year followwith reduced survival in a 10-year followup of 88 people with schizophrenia. In a up of 88 people with schizophrenia. In a French study the mortality among patients French study the mortality among patients with chronic schizophrenia was associated with chronic schizophrenia was associated with the dosage of neuroleptics (Bralet with the dosage of neuroleptics (Bralet et et al al, 2000) . Why is more than one neuro-, 2000). Why is more than one neuroleptic drug prescribed? We can presume leptic drug prescribed? We can presume that one reason might be the lack of rethat one reason might be the lack of response to a single antipsychotic, possibly sponse to a single antipsychotic, possibly related to the severity of the illness. Is it also related to the severity of the illness. Is it also possible that the most severe forms of possible that the most severe forms of schizophrenia carry a higher risk of dying schizophrenia carry a higher risk of dying than less severe schizophrenia. However, than less severe schizophrenia. However, it must be borne in mind that antipsychotic it must be borne in mind that antipsychotic polypharmacy can also lead to increased polypharmacy can also lead to increased side-effects because of the potential influside-effects because of the potential influence on many receptors in addition to brain ence on many receptors in addition to brain D D 2 2 dopamine receptors (Waddington dopamine receptors (Waddington et al et al, , 1998 (Waddington et al et al, , ). 1998 .
If classic neuroleptics were the cause of If classic neuroleptics were the cause of premature deaths among people with premature deaths among people with schizophrenia it could be assumed that the schizophrenia it could be assumed that the excess mortality would have decreased with excess mortality would have decreased with the introduction of the newer atypical antithe introduction of the newer atypical antipsychotics. However, a Swedish study psychotics. However, a Swedish study found an increase in mortality in patients found an increase in mortality in patients with schizophrenia (Osby with schizophrenia (Osby et al et al, 2000) . , 2000). The newer atypical antipsychotic agents The newer atypical antipsychotic agents can affect somatic health in different ways can affect somatic health in different ways (Wirshing (Wirshing et al et al, 2003) . , 2003).
Study strengths and limitations Study strengths and limitations
The strengths of the present study included The strengths of the present study included a long follow-up and a representative a long follow-up and a representative sample with a high participation rate. sample with a high participation rate.
Because of the comprehensive nature of Because of the comprehensive nature of the Mini-Finland Health Survey we were the Mini-Finland Health Survey we were able to take many potential confounding able to take many potential confounding factors into account. The main screening factors into account. The main screening instrument used, the General Health instrument used, the General Health Questionnaire, is most suitable for screenQuestionnaire, is most suitable for screening for non-psychotic psychiatric illnesses ing for non-psychotic psychiatric illnesses such as anxiety and mood disorders. such as anxiety and mood disorders. However, other aspects of our screening However, other aspects of our screening procedure, especially review of the SII procedure, especially review of the SII records concerning disability pensions and records concerning disability pensions and reimbursement for medicines used to treat reimbursement for medicines used to treat severe mental disorders, identified those severe mental disorders, identified those with psychotic disorders. Another limitawith psychotic disorders. Another limitation was that we were not able to define tion was that we were not able to define the total period of neuroleptic use or total the total period of neuroleptic use or total dosage or to assess the impact of prior dosage or to assess the impact of prior treatment. In addition, the number of treatment. In addition, the number of people with schizophrenia was relatively people with schizophrenia was relatively low, only 99, of whom 39 died during low, only 99, of whom 39 died during follow-up. In spite of these limitations we follow-up. In spite of these limitations we consider the results valid. The association consider the results valid. The association of the use of neuroleptic drugs and of the use of neuroleptic drugs and mortality poses questions which could not mortality poses questions which could not be answered in this study. A careful quantibe answered in this study. A careful quantitative analysis of the association of neurotative analysis of the association of neuroleptic drug dosage and mortality would be leptic drug dosage and mortality would be especially interesting. especially interesting.
Conclusions Conclusions
More attention should be paid to the More attention should be paid to the somatic health of people with schizosomatic health of people with schizophrenia. Our results indicate a need to phrenia. Our results indicate a need to modify the deleterious lifestyle factors of modify the deleterious lifestyle factors of patients with schizophrenia previously patients with schizophrenia previously recommended by Brown recommended by Brown et al et al (2000) . The (2000) . The recognition and medical management of recognition and medical management of somatic diseases among people with schizosomatic diseases among people with schizophrenia is a challenge to psychiatrists. Fuphrenia is a challenge to psychiatrists. Future research needs to determine whether ture research needs to determine whether the high mortality among those with the high mortality among those with schizophrenia is mainly attributable to the schizophrenia is mainly attributable to the disorder per se or to the antipsychotic medidisorder per se or to the antipsychotic medication. Study of the association between the cation. Study of the association between the newer antipsychotic drugs and mortality newer antipsychotic drugs and mortality in patients with schizophrenia will be in patients with schizophrenia will be important after a sufficient period of treatimportant after a sufficient period of treatment has elapsed to allow long-term ment has elapsed to allow long-term follow-up. follow-up.
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